Los Angeles Capital Management LLC Boosts Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Los Angeles Capital Management LLC grew its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 138.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 201,439 shares of the company’s stock after purchasing an additional 116,853 shares during the period. Los Angeles Capital Management LLC owned approximately 0.58% of RAPT Therapeutics worth $405,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. raised its stake in shares of RAPT Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after purchasing an additional 3,824 shares during the period. Acadian Asset Management LLC bought a new stake in shares of RAPT Therapeutics in the first quarter worth $97,000. EntryPoint Capital LLC bought a new stake in shares of RAPT Therapeutics in the first quarter worth $161,000. Bank of New York Mellon Corp increased its stake in shares of RAPT Therapeutics by 24.0% in the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after buying an additional 22,175 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of RAPT Therapeutics in the second quarter worth $108,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 13.7 %

Shares of NASDAQ RAPT opened at $1.11 on Monday. RAPT Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $27.35. The firm’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $2.92. The stock has a market cap of $38.63 million, a P/E ratio of -0.40 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, sell-side analysts anticipate that RAPT Therapeutics, Inc. will post -2.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, November 12th. UBS Group dropped their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th. Stifel Nicolaus restated a “hold” rating and issued a $2.00 price target (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Finally, Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $8.00 to $2.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.50.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.